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Abstract
Objective To assess the overlap of and differences between quantitative muscle MRI and ultrasound in characterizing struc-
tural changes in leg muscles of facioscapulohumeral muscular dystrophy (FSHD) patients.
Methods We performed quantitative MRI and quantitative ultrasound of ten leg muscles in 27 FSHD patients and assessed 
images, both quantitatively and visually, for fatty infiltration, fibrosis and edema.
Results The MRI fat fraction and ultrasound echogenicity z-score correlated strongly (CC 0.865, p < 0.05) and both correlated 
with clinical severity (MRI CC 0.828, ultrasound CC 0.767, p < 0.001). Ultrasound detected changes in muscle architecture 
in muscles that looked normal on MRI. MRI was better in detecting late stages of fatty infiltration and was more suitable to 
assess muscle edema. Correlations between quantitative and semi-quantitative scores were strong for MRI (CC 0.844–0.982, 
p < 0.05), and varied for ultrasound (CC 0.427–0.809, p = 0.026–p < 0.001).
Conclusions Quantitative muscle MRI and ultrasound are both promising imaging biomarkers for differentiating between 
degrees of structural muscle changes. As ultrasound is more sensitive to detect subtle structural changes and MRI is more 
accurate in end stage muscles and detecting edema, the techniques are complementary. Hence, the choice for a particular 
technique should be considered in light of the trial design.
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Introduction
Muscle imaging complements the clinical assessment of 
muscle disorders. It reveals patterns and severity of muscle 
involvement that can help guide diagnosis and track dis-
ease progression [1]. Facioscapulohumeral muscular dys-
trophy (FSHD) is a slowly progressive inherited muscle 
disorder [2]. Recent insights in its pathogenic mechanism 
are expected to be translated into targeted therapies soon 
[3, 4]. Clinical trials are expected in the upcoming years, 
requiring (imaging) biomarkers for the assessment of muscle 
involvement and disease progression [5]. Especially, in early 
phase trials, the use of highly responsive biomarkers would 
enable a smaller sample size or a shorter follow-up period, 
and therefore a more efficient screening of potential thera-
pies, compared to clinical outcome measures. In FSHD, 
muscle MRI is currently the most frequently used imaging 
technique in research studies. It is able to detect and quan-
tify fatty infiltration of muscle tissue and visualize muscle 
edema. The degree of fatty infiltration on MRI correlates 
strongly to clinical measures and it is able to capture changes 
over time [6–8].
Muscle ultrasound may provide an alternative that is 
patient-friendly, safe, fast and can be performed at the bed-
side [9]. Various structural changes in the muscle, such as 
fatty infiltration, fibrosis, or edema, produce an increase in 
echogenicity. Especially, the presence of fibrosis is strongly 
correlated with an echogenicity increase [10–12]. Increased 
muscle ultrasound echogenicity correlated strongly with 
decreased muscle strength in different neuromuscular disor-
ders [13–15]. In Duchenne muscular dystrophy, it was shown 
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to be sensitive to disease progression [16, 17]. A disadvan-
tage is its inability to measure deeper layers of muscle. Lim-
ited work has been done comparing quantitative ultrasound 
and MRI head-to-head. Measurements of muscle thickness, 
length and cross-sectional area were shown to yield simi-
lar results for both techniques [18–20]. In a pilot-study on 
five male FSHD patients, ultrasound was shown to correlate 
with, but also complement MRI data [21]. The promising 
results of this pilot, prompted us to evaluate the properties 
of both techniques and compare them in a larger and clini-
cally more diverse FSHD cohort. The aim of this study is to 
assess the overlap and the additional value of quantitative 
muscle MRI and ultrasound in leg muscles. This includes 
assessment of structural muscle changes, correlating imag-




We included genetically confirmed FSHD patients of 
18 years and older. A genetic diagnosis of FSHD1 was 
defined as a D4Z4 repeat array on chromosome four of ten 
D4Z4 repeat units or less on a permissive haplotype, and for 
FSHD2 as an SMCHD1 pathogenic variant and hypometh-
ylation of the D4Z4 repeat array on chromosome 4q35. This 
study was performed in conjunction with a large MRI study 
on FSHD patients (n = 140) [6]. A random subset of patients 
participating in the last five months of the MRI study 
(between June and October 2015) additionally underwent 
muscle ultrasound. The selection of patients was based on 
the availability of the ultrasound equipment. This study was 
conducted according to the principles of the Declaration of 
Helsinki (version October 2013) and in accordance with the 
Medical Research Involving Human Subjects Act (WMO). 
The study protocol was approved by the regional medical 
ethics committee (CMO region Arnhem–Nijmegen). All 
patients signed informed consent prior to their inclusion in 
the study.
MRI acquisition and analysis
A detailed description of the MRI scanning protocol and 
quantitative analysis can be found elsewhere [6]. The MRI 
exams were performed on a 3-Tesla MR system (TIM Trio; 
Siemens, Erlangen, Germany). In summary, we acquired 
scout images in three orthogonal directions for position-
ing of imaging slices. Next, both legs were scanned using a 
Dixon 2.0 sequence and a TIRM sequence with a slice thick-
ness of 5 mm [22]. Regions of interest (ROI) were drawn 
on a fat fraction map of the Dixon sequence for the muscles 
of interest. We made a selection of frequently affected and 
spared muscles in FSHD that are suited for ultrasound 
measurement: the rectus femoris, vastus lateralis, peroneus 
tertius, tibialis anterior and medial gastrocnemius bilater-
ally. ROI’s were drawn at specific slices using the localizer 
sequences: rectus femoris halfway between anterior superior 
iliac spine (ASIS) and upper pole of patella, vastus lateralis 
at two-thirds between ASIS and the upper lateral margin of 
patella, tibialis anterior at one-third from the inferior border 
of the patella to the lateral malleolus, peroneus tertius at 
one-fifth from the lateral malleolus to the fibular head and 
the medial head of gastrocnemius at one-third from the pop-
liteal fossa to the medial malleolus. A fish oil capsule that 
could be visualized on the MRI images was placed on the 
skin to ensure that ultrasound images were obtained at the 
same level as the MRI images. Muscle fat fractions were cal-
culated per ROI (Fig. 1). Fat fractions below 15% are consid-
ered normal [23]. In addition, MRI images per muscle were 
visually scored by one investigator (KM) using the modified 
Lamminen scale. Fatty infiltration was scored as: 0 = normal; 
1 = mild with only traces of fatty infiltration; 2 = moderate 
with fatty infiltration in less than 50% of the muscle tissue; 
3 = severe with fatty infiltration in more than 50% of the 
muscle tissue; 4 = the entire muscle replaced by abnormal 
signal [24, 25]. TIRM images were visually assessed for the 
presence of signal hyperintensity in each muscle at the loca-
tion corresponding to the ultrasound images by a radiologist 
and one investigator (KM). The assessors of the MRI images 
were blinded for the ultrasound results and vice versa, but 
not for clinical status of the patient.
Ultrasound acquisition and analysis
Muscle ultrasound was performed using an Esaote 
MyLabTwice ultrasound scanner (Esaote SpA, Genoa, 
Italy) using an 8–14 MHz broadband linear transducer 
with a 53-mm footprint, that has an axial resolution of 
around 0.2 mm. The ultrasound protocol was previously 
reported elsewhere [21]. In summary, a preset for system 
settings was used to ensure compatibility between meas-
urements. Three consecutive measurements were per-
formed to minimize variation in echo intensity. Results 
were averaged offline. Transverse images were acquired 
at the same locations as described above for the MRI. 
Patients were in supine position with the legs in resting 
position. For correct echo intensity measurements, oblique 
scanning angles were avoided by adjusting the angle of 
the probe to obtain optimal perpendicular imaging of the 
underlying bone. For every muscle, a ROI was drawn 
manually using custom software, developed at our center 
(Fig. 1). Raw muscle echo intensities were calculated 
per ROI and then converted to z-scores (the number of 
standard deviations from the mean score for sex, age and 
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weight) using previously established reference values [26]. 
These z-scores were used for statistical analyses. z-scores 
below 2.0 (i.e., below the population 95th percentile) are 
considered normal.
A semi-quantitative assessment of the images was per-
formed using the Heckmatt rating scale which ranges from 
one (normal echo intensity) to four (severely increased 
echo intensity with absent bone reflection) by an experi-
enced neuromuscular ultrasonographer (NvA) [27]. Ultra-
sound images were visually inspected for textural changes 
of muscle tissue. We assessed ultrasound images for the 
presence of edema by looking for the characteristic pat-
tern that is seen in inflammatory myopathies: a blurring 
of muscle architecture with “see through” echogenicity 
increase without decrease in echogenicity in the deeper 
part of the muscle [28].
Clinical outcome measures
Disease severity was rated using the FSHD clinical score, a 
15-point sum score that evaluates different muscle groups, 
where zero indicates no muscle weakness and 15 severe 
muscle weakness in all muscle groups [29]. The motor 
function measure (MFM) was chosen as a functional out-
come measure. It assesses the severity of the motor deficit 
on a 32-item scale with outcomes ranging from 0 to 100% 
in which 100% implies no motor deficits [30]. Muscle 
strength was tested manually (MRC gradation [31]) for the 
Fig. 1  a MR image of left upper leg with a region of interest drawn 
for a normal looking rectus femoris muscle. b The corresponding 
ultrasound image to a. c MR image of left upper leg with a region of 
interest drawn for a dystrophic rectus femoris muscle. d The corre-
sponding ultrasound image to c. S: sartorius; G: gracilis; VM: vastus 
medialis; VI: vastus intermedius; VL; vastus lateralis; AL: adductor 
longus; AM: adductor magnus
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knee extensors, foot dorsiflexors and foot plantar flexors, and 
quantitatively (fixed dynamometry) for the knee extensors.
Statistical analyses
All statistical analyses were performed using IBM SPSS 
Statistics, version 22. Because of the skewed distribution 
of fat fractions and z-scores, a Spearman rho analysis was 
used to calculate bivariate correlations between MRI and 
ultrasound. The Spearman rho analysis was also used for 
correlations between quantitative and semi-quantitative 
scores. For correlations between clinical outcome measures 
and fat fractions and z-score, the Pearson correlation coef-
ficient was used. To control for multiple testing, we applied 
the Benjamini–Hochberg false discovery rate procedure, a 
less conservative method than the Bonferroni correction, in 




We included 27 genetically confirmed FSHD patients com-
prising the full spectrum of disease severity. Of these, one 
was an asymptomatic gene carrier who only showed minimal 
signs of FSHD on examination, mainly abdominal muscle 
weakness. This resulted in analyzing 270 lower extremity 
muscles. Patient characteristics are presented in Table 1. For 
each patient, muscle MRI and ultrasound were performed on 
the same day. There were no differences between FSHD1 
and FSHD2 patients in either imaging or clinical outcomes.
Correlation between MRI and ultrasound
The mean MRI fat fraction of all muscles per patient cor-
related highly and significantly with the mean ultrasound 
z-score with a correlation coefficient of 0.865 (p < 0.001). 
When correlating MRI fat fraction and ultrasound z-score 
per muscle for both legs separately, all correlations were 
statistically significant (p < 0.05 after correction for multi-
ple testing), but correlation coefficients varied widely from 
0.514 to 0.873 (Fig. 2). As can be noted in Fig. 2, in all mus-
cles measured except for the tibialis anterior, the ultrasound 
z-scores often decrease towards normal at muscle sites with 
the highest fat fractions on MRI. In approximately 15% of 
all muscles, there was a high MRI fat fraction but a normal 
ultrasound z-score, or vice versa.
Nineteen muscles appeared (nearly) normal on the MRI, 
but showed increased ultrasound z-scores. On visual inspec-
tion of these ultrasound images, the muscles showed tissue 
texture changes, consisting of an increased amount of short 
linear reflective structures that overall increased echogenic-
ity. Such changes are consistent with intramuscular fibrosis, 
especially in the absence of fatty infiltration (Fig. 3a, b) [10, 
11].
Twenty of the outliers were muscles that were severely 
fatty infiltrated on MRI, but had normal ultrasound z-scores 
(Fig. 3c, d). On visual inspection of these ultrasound images, 
the muscle tissue appeared relatively hypoechogenic, but 
muscle architecture was disturbed on all these images. This 
was most often seen in the medial gastrocnemius muscle.
Five of the outliers demonstrated heterogenous involve-
ment of the muscle. The ultrasound measurement was per-
formed at a site where only fatty infiltrated or only normal 
looking muscle tissue was present. In contrast, the MR 
image included the total cross-sectional area of the muscle 
(Fig. 3e, f).
Asymmetrical muscle involvement was found in 25/135 
(18.5%) of all muscle pairs. In 14 muscle pairs, there was 
asymmetry both on MRI and on ultrasound images. In 11 
muscle pairs there was asymmetry only on images of one of 
the two techniques and these were the muscles where MRI 
and ultrasound showed different results as described above.
Muscle edema
The MRI showed TIRM hyperintense areas, indicating 
muscle edema, in 22 (8%) of 270 muscles. Two of these 22 
TIRM positive muscles, both tibialis anterior muscles, also 
scored positively for inflammation on muscle ultrasound. 
Another 32 muscles were also scored positive for inflamma-
tion on muscle ultrasound, but were TIRM negative on MRI. 
These 32 muscles all had a fat fraction below 15% except for 
one medial gastrocnemius (fat fraction 18.2%). In 29 out of 
32 muscles, this involved the vastus lateralis, rectus femoris 
or medial gastrocnemius muscles. The 19 outliers mentioned 
above, showing an increased z-score on ultrasound images, 
but normal fat fraction on MRI images, were all TIRM nega-
tive. TIRM hyperintense areas were found both in muscle 
with and without fatty infiltration.
Table 1  Patient characteristics
N = 27
Sex Male n = 17
Female n = 10
Age (mean ± SD [range]) 53.2 years ± 12.7 [31–78] 
BMI (mean ± SD [range]) 26.3 kg/m2 ± 4.1 [21.0–35.3]
FSHD type FSHD1 n = 25
FSHD2 n = 2
FSHD clinical score
(mean ± SD [range])
5.5 ± 3.8 [14, [0–14]]
Motor function measure (mean ± SD 
[range])
86.6 ± 17.7 [29.1–100]
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Correlation between imaging results and clinical 
outcome measures
Both the mean MRI fat fraction and mean ultrasound z-score 
of all muscles correlated strongly with the FSHD clinical 
score, a measure of disease severity (correlation coefficients 
0.828 and 0.767, respectively, p < 0.001) and with the motor 
function measure, a functional outcome measure (correlation 
coefficients − 0.826 and − 0.674, respectively, p < 0.001). 
Correlations of muscle strength testing with the MRI fat 
fraction and ultrasound z-score of the corresponding muscle 
group are shown in Table 2.
Fig. 2  Correlation between quantitative MRI (fat fraction) and ultra-
sound (z-score) for the mean values of all muscles and for each mus-
cle separately. The fat fractions and z-scores for the total legs were 
calculated by averaging the scores for the ten muscles measured. Dot-
ted lines indicate limits of values that are considered normal. CC: 
correlation coefficient
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Fig. 3  a, b Images of the right vastus lateralis, appearing normal on 
MRI (fat fraction 6%) but showing textural changes tissue texture 
changes (an increased amount of short linear reflective structures) 
on ultrasound images, resulting in a high echo intensity (z-score 3.4). 
c, d MRI of the left gastrocnemius medialis that is completely fatty 
infiltrated (fat fraction 74%) and the corresponding ultrasound image 
that shows a low echo intensity (resulting in a normal z-score of 0.6), 
but a disturbed architecture of the muscle tissue. e, f MRI of the right 
vastus lateralis with focal fatty infiltration (fat fraction 21%) and the 
corresponding ultrasound image, capturing only the fatty infiltrated 
part of the muscle (z-score 7.1)
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We separately evaluated the clinical involvement of the 19 
muscles showing an increased z-score on ultrasound images, 
but normal fat fraction on MRI images. Manual muscle test-
ing of the corresponding muscle group was normal in all but 
two patients. One patient with increased ultrasound z-score 
of the gastrocnemius medialis muscle had mild weakness of 
the plantar flexors (MRC 4), but also had a fatty infiltrated 
soleus muscle. One patient with a high z-score for the vas-
tus lateralis muscle scored MRC4 for knee extensors, but 
additionally showed fatty infiltration of other parts of the 
quadriceps muscle.
TIRM hyperintense areas were found both in muscle 
with normal and with decreased strength. In muscles with 
decreased strength, there was a combination of fatty infiltra-
tion and TIRM hyperintensity.
Correlation between quantitative 
and semi‑quantitative rating scales
MRI quantitative muscle fat fractions correlated moderately 
to strongly with the semi-quantitative modified Lamminen 
score for all muscles (correlation coefficient ranging from 
0.641 to 0.891, p < 0.01 corrected for multiple testing). Cor-
relations of quantitative ultrasound and the semi-quantita-
tive Heckmatt score, were less strong, but still significant 
(range 0.418–0.840, p < 0.05 corrected for multiple testing) 
for all muscles. Moderate correlations were found for left 
Table 2  Correlations between 
muscle strength testing and 
imaging outcomes of the 
corresponding muscle groups
p values corrected for multiple testing
MMT: manual muscle testing; QMT: quantitative muscle testing; CC: correlation coefficient
Clinical outcome Muscle MRI fat fraction Ultrasound z-score
CC p value CC p value
MMT dorsiflexors Tibialis anterior
 Right − 0.882 0.01 − 0.772 0.01
 Left − 0.886 0.01 − 0.729 0.01
MMT plantar flexors Gastrocnemius medialis
 Right − 0.323 0.16 − 0.580 0.01
 Left − 0.378 0.08 − 0.569 0.01
MMT knee extensors Vastus lateralis
 Right − 0.823 0.01 − 0.543 0.01
 Left − 0.828 0.01 − 0.569 0.01
Rectus femoris
 Right − 0.500 0.02 − 0.335 0.14
 Left − 0.535 0.01 − 0.230 0.30
QMT knee extensors Vastus lateralis
 Right − 0.603 0.01 − 0.492 0.03
 Left − 0.522 0.02 − 0.232 0.32
Rectus femoris
 Right − 0.385 0.08 − 0.289 0.23
 Left − 0.123 0.57 − 0.159 0.46
Table 3  Correlations between quantitative and semi-quantitative 
scores per muscle for both MRI and ultrasound images
p values corrected for multiple testing
Muscle MRI





CC p value CC p value
Rectus femoris
 Right 0.865 0.01 0.717 0.01
 Left 0.818 0.01 0.763 0.01
Vastus lateralis
 Right 0.795 0.01 0.651 0.01
 Left 0.762 0.01 0.418 0.01
Tibialis anterior
 Right 0.835 0.01 0.840 0.01
 Left 0.835 0.01 0.749 0.01
Gastrocnemius medialis
 Right 0.891 0.01 0.677 0.01
 Left 0.745 0.01 0.582 0.01
Peroneus tertius
 Right 0.652 0.01 0.742 0.01
 Left 0.641 0.01 0.805 0.01
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gastrocnemius and vastus lateralis muscle. All correlation 
coefficients are presented in Table 3.
Discussion
This study of 270 leg muscles of 27 patients with different 
stages of FSHD showed that both quantitative muscle MRI 
and quantitative ultrasound correlated strongly with clinical 
disease severity and with most of the manual muscle strength 
testing. There was a strong correlation between the degree of 
fatty infiltration on MRI and the ultrasound echo intensity. 
The head-to-head comparison provided unique insights into 
the strengths and pitfalls of both techniques. While for most 
muscles the techniques yielded similar results, there were 
differences between the two techniques in approximately 
15% of the muscles measured.
For some muscles ultrasound detected changes suggestive 
of intramuscular fibrosis, leading to increased echogenicity, 
while MR images were still normal both visually and quan-
titatively. Whereas MRI only detects fatty infiltration and 
edema, ultrasound also detects fibrosis. A study on FSHD 
patients using muscle biopsies from tibialis anterior and vas-
tus lateralis muscles that appeared normal on MRI, showed 
mild to moderate fibrosis in 11 of 17 biopsies (65%) (unpub-
lished data). Two animal studies have shown that fibrosis 
leads to increased muscle echo intensity [10, 12]. However, 
as we did not perform muscle biopsies in this study, there 
is no direct pathological evidence to attribute the disturbed 
muscle architecture to fibrosis. Altogether, our findings sug-
gest that muscle involvement in FSHD starts even before 
signs of fatty infiltration or edema become apparent on 
MRI, and that MRI is not able to detect all structural muscle 
changes. Whether these changes on ultrasound have an effect 
on muscle strength could not be determined, because the 
muscles involved perform their function as a part of a larger 
muscle group. Longitudinal data are necessary to determine 
the evolvement of these changes in muscle architecture. For 
clinical trials on therapeutic agents intended to slow down 
disease progression, patients with early disease stage are an 
important target group. For this particular group, quantita-
tive ultrasound may be a more suitable biomarker than MRI.
In contrast, in muscles that were nearly completely 
replaced by fat on MRI, ultrasound often failed to detect the 
degree of abnormality. This can be explained by the fact that 
in severely fatty infiltrated muscles, there will be few tissue 
transitions left to reflect the ultrasound beam, resulting in a 
relatively hypoechoic image. However, on visual inspection, 
the ultrasound images showed an abnormal muscle texture. 
Thus, in these cases, new techniques for texture analysis 
might provide an increased detection of muscle involvement 
over grayscale/echogenicity analysis [33]. This difference 
between techniques was observed most frequently in the 
medial gastrocnemius muscle, that often shows early and 
severe involvement in FSHD [6]. For the calf muscles, the 
misleading decrease in echogenicity in severely affected 
muscles has been described earlier [34], but the current 
study shows that this is also the case for other muscles, such 
as the rectus femoris, vastus lateralis and peroneus tertius. In 
longitudinal studies on severely affected muscles, quantita-
tive ultrasound measurements bare the risk of false positive 
results, since a decrease in z-score could be due to the mus-
cle becoming more fatty infiltrated. In this particular patient 
group, muscle MRI would be the preferred biomarker.
A small proportion of all muscles (0.2%) showed inho-
mogeneous distribution of fatty infiltration within the mus-
cle on MRI. Here, the smaller sampling area of the ultra-
sound images resulted in different results between the two 
techniques. For most muscles in FSHD the pattern of fatty 
infiltration is homogeneous, although it can vary along the 
length of a muscle [6, 35]. For other muscle disorders with 
a more patchy distribution such as inflammatory myopathies 
this poses a risk of sampling error when imaging these with 
ultrasound [36]. Quantitative ultrasound is currently only 
able to measure superficially located muscles and can often 
measure only a part of the muscle. Thus, in this case, MRI 
has the advantage of depicting all leg muscles over their 
entire length.
In the assessment of muscle edema, MRI and ultrasound 
yielded very disparate results, with a higher proportion of 
muscles scored positive for edema on ultrasound images. 
For MRI, different sequences can be applied to discrimi-
nate between signal changes due to fatty infiltration or mus-
cle edema. With muscle ultrasound, however, a variety of 
changes in the composition of the muscle tissue can pro-
duce increased echogenicity. For the assessment of edema 
on ultrasound images, we looked for signs that are typically 
seen in inflammatory myopathies. As these myopathies have 
a different pathogenic mechanism compared to FSHD, this 
definition for edema may not be suited to assess FSHD mus-
cles. Additionally, a muscle can only be positive for edema 
when it is mildly fatty infiltrated, because in moderate or 
severely fatty infiltrated muscles there is always a decrease 
in echogenicity in the deeper layers of the muscle due to 
attenuation of the ultrasound beam, and hence no “see-
through”. As there currently is no better method to discern 
increased echogenicity due to fat and/or fibrosis from edema, 
MRI remains the more suitable technique to assess muscle 
inflammation thus far [37].
Finally, the suboptimal correlation between quantita-
tive and semi-quantitative ultrasound scores in this study 
emphasizes the challenges in scoring ultrasound images vis-
ually. Even the use of a semi-quantitative rating such as the 
Heckmatt scale cannot capture all variables that influence 
the degree of abnormality. Additionally, qualitative meas-
ures are ordinal, non-linear, measures that are not suited 
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for parametric statistical testing. For MRI, quantitative and 
semi-quantitative assessments correlated strongly, but both 
failed to detect architectural changes in some muscles that 
were abnormal on ultrasound images.
The main limitation of this study was the relative small 
sample size. Though we included the full spectrum of dis-
ease severity, the population was limited in the sense that 
it did not include children or severely obese individuals. 
Longitudinal studies will be essential to assess evolvement 
of MRI and ultrasound abnormalities and their relation to 
one another.
In conclusion, quantitative muscle MRI and ultrasound 
were both able to differentiate between different degrees 
of muscle involvement and correlated strongly to clinical 
severity. At the ends of the severity spectrum, the two tech-
niques complement each other in detecting structural muscle 
changes. The choice for a particular technique should there-
fore be carefully considered in light of the target population, 
the clinical or research question and muscles to be measured.
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